Novartis Q4 Results
↓
↑
Content
Click below to navigate
through the document
BeovuⓇ - VEGF Inhibitor
Company overview
Financial review
Conclusions
NCT04278417 CONDOR (CRTH258D2301)
Diabetic retinopathy
Phase 3
Indication
Phase
Patients
694
Change from Baseline in BCVA
Arm 1: RTH258 (brolucizumab) 6 mg/50uL
Arm 2: Panretinal photocoagulation laser initial treatment followed with additional
PRP treatment as needed
Patients with proliferative diabetic retinopathy
Appendix
Innovation: Pipeline overview
Financial performance
Innovation: Clinical trials
Cardiovascular, Renal
and Metabolic
Immunology
Neuroscience
Oncology
> Other
Global Health
Abbreviations
Primary
Outcome
Measures
Arms
Intervention
Target Patients
Readout
Milestone(s)
2024
Publication
TBD
References
□ NOVARTIS Reimagining Medicine
Novartis Q4 Results | January 31, 2024
80View entire presentation